Abstract
The human pathogen, group A rotavirus, is the most prevalent cause of acute infantile and pediatric gastroenteritis worldwide, especially in developing countries. There is an urgent demand for safer, more effective and cheaper vaccines against rotavirus infection. Plant-derived antigens may provide an exclusive way to produce economical subunit vaccines. Virus-like particles, constituting viral capsid proteins without viral nucleic acids, are considered a far safer candidate compared with live attenuated viral vaccines. In this study, the rotavirus capsid proteins VP2, VP6 and VP7 were co-expressed in transgenic tobacco plants, and their expression levels, formation of rotavirus-like particles (RV VLPs) and immunogenicity were extensively studied. Quantitative real-time RT-PCR and Western blot analysis revealed that the expression level of vp6 was the highest while vp7 was expressed at the lowest levels. The RV VLPs were purified from transgenic tobacco plants and analyzed by electron microscopy and Western blot. Results indicated that the plant-derived VP2, VP6 and VP7 proteins self-assembled into 2/6 or 2/6/7 RV VLPs with a diameter of 60–80 nm. When orally delivered into mice with cholera toxin as an adjuvant, the total soluble protein extracted from transgenic tobacco plants induced rotavirus-specific antibodies comparable with those of attenuated rotavirus vaccines, while VP 2/6/7 induced higher serum IgG and fecal IgA titers compared with VP 2/6.
Article PDF
Similar content being viewed by others
References
O’Ryan M, Prado V, Pickering L K. A millennium update on pediatric diarrheal illness in the developing world. Semin Pediatr Infect Dis, 2005, 16: 125–136, 10.1053/j.spid.2005.12.008, 15825143
Banos D M, Lopez S, Arias C F, et al. Identification of a T-helper cell epitope on the rotavirus VP6 protein. J Virol, 1997, 71: 419–426, 1:CAS:528:DyaK28XnsF2gsLc%3D, 8985366
Estes M K, Crawford S E, Penaranda M E, et al. Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system. J Virol, 1987, 61: 1488–1494, 1:CAS:528:DyaL2sXktFyrsbc%3D, 3033276
Offit P A, Shaw R D, Greenberg H B. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7. J Virol, 1986, 58: 700–703, 1:CAS:528:DyaL28Xit1eisbY%3D, 2422398
Matsui S M, Offit P A, Vo P T, et al. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J Clin Microbiol, 1989, 27: 780–782, 1:STN:280:DyaL1M3lsFyrsw%3D%3D, 2470774
Mackow E R, Vo P T, Broome R, et al. Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge. J Virol, 1990, 64: 1698–1703, 1:CAS:528:DyaK3cXhslKlsro%3D, 2157052
Andrew M E, Boyle D B, Coupar B E, et al. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea. Vaccine, 1992, 10: 185–191, 1:STN:280:DyaK383htl2qsg%3D%3D, 10.1016/0264-410X(92)90010-H, 1313627
Both G W, Lockett L J, Janardhana V, et al. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virol, 1993, 193: 940–950, 1:CAS:528:DyaK3sXitFSqtL4%3D, 10.1006/viro.1993.1203
Kapikian A Z, Hoshino Y, Chanock R M, et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis, 1996, 174: S65–72, 8752293
Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. Jama, 1999, 282: 2113–2114, 10.1001/jama.282.22.2113
Madhi S A, Cunliffe N A, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med, 2010, 362: 289–298, 1:CAS:528:DC%2BC3cXht1aqt7w%3D, 10.1056/NEJMoa0904797, 20107214
Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med, 2010, 362: 299–305, 1:CAS:528:DC%2BC3cXht1aqt70%3D, 10.1056/NEJMoa0905211, 20107215
Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine, 2004, 22: 2836–2842, 1:CAS:528:DC%2BD2cXls1Wkt7Y%3D, 10.1016/j.vaccine.2004.01.044, 15246619
Ruiz-Palacios G M, Perez-Schael I, Velazquez F R, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med, 2006, 354: 11–22, 1:CAS:528:DC%2BD28XhvVWltw%3D%3D, 10.1056/NEJMoa052434, 16394298
Vesikari T, Clark H F, Offit P A, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine, 2006, 24: 4821–4829, 1:CAS:528:DC%2BD28XltF2qsrk%3D, 10.1016/j.vaccine.2006.03.025, 16621194
Choi A H, Basu M, Rae M N, et al. Particle-bombardment-mediated DNA vaccination with rotavirus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge. Virol, 1998, 250: 230–240, 1:CAS:528:DyaK1cXmvVSis78%3D, 10.1006/viro.1998.9370
Bachmann M F, Rohrer U H, Kundig T M, et al. The influence of antigen organization on B cell responsiveness. Science, 1993, 262: 1448–1451, 1:CAS:528:DyaK2cXlt1WnsA%3D%3D, 10.1126/science.8248784, 8248784
Bachmann M F, Zinkernagel R M, Oxenius A. Immune responses in the absence of costimulation: Viruses know the trick. J Immunol, 1998, 161: 5791–5794, 1:CAS:528:DyaK1cXnslCrsr8%3D, 9834052
Jiang X, Wang M, Graham D Y, et al. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol, 1992, 66: 6527–6532, 1:CAS:528:DyaK3sXjsFCl, 1328679
Ciarlet M, Crawford S E, Barone C, et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol, 1998, 72: 9233–9246, 1:CAS:528:DyaK1cXmslahsLY%3D, 9765471
McNeal M M, Rae M N, Conner M E, et al. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virol, 1998, 243: 158–166, 1:CAS:528:DyaK1cXit1Gnurk%3D, 10.1006/viro.1998.9060
O’Neal C M, Clements J D, Estes M K, et al. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol, 1998, 72: 3390–3393, 9525668
Yuan L, Geyer A, Hodgins D C, et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol, 2000, 74: 8843–8853, 1:CAS:528:DC%2BD3cXmslymsL8%3D, 10.1128/JVI.74.19.8843-8853.2000, 10982326
Yuan L, Saif L J. Induction of mucosal immune responses and protection against enteric viruses: Rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol, 2002, 87: 147–160, 1:CAS:528:DC%2BD38XksFKktLc%3D, 10.1016/S0165-2427(02)00046-6, 12072229
Conner M E, Crawford S E, Barone C, et al. Rotavirus subunit vaccines. Arch Virol, 1996, 12: 199–206, 1:STN:280:DyaK2s7mslChtQ%3D%3D
Jiang B, Estes M K, Barone C, et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine, 1999, 17: 1005–1013, 1:STN:280:DyaK1M7msFSgsA%3D%3D, 10.1016/S0264-410X(98)00317-X, 10067709
Coste A, Sirard J C, Johansen K, et al. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. J Virol, 2000, 74: 8966–8971, 1:CAS:528:DC%2BD3cXmslymsbs%3D, 10.1128/JVI.74.19.8966-8971.2000, 10982340
Cimolai N. Do mycoplasmas cause human cancer? Can J Microbiol, 2001, 47: 691–697, 1:CAS:528:DC%2BD3MXnt12gurw%3D, 10.1139/cjm-47-8-691, 11575494
Streatfield S J, Howard J A. Plant production systems for vaccines. Expert Rev Vaccines, 2003, 2: 763–775, 10.1586/14760584.2.6.763, 14711360
Tacket C O. Plant-derived vaccines against diarrhoeal diseases. Expert Opin Biol Ther, 2004, 4: 719–728, 1:CAS:528:DC%2BD2cXjsVeksbo%3D, 10.1517/14712598.4.5.719, 15155163
Streatfield S J. Oral hepatitis B vaccine candidates produced and delivered in plant material. Immunol Cell Biol, 2005, 83: 257–262, 1:CAS:528:DC%2BD2MXmtVSit78%3D, 10.1111/j.1440-1711.2005.01335.x, 15877603
Mason H S, Ball J M, Shi J J, et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA, 1996, 93: 5335–5340, 1:CAS:528:DyaK28Xjt1Kqu7c%3D, 10.1073/pnas.93.11.5335, 8643575
Warzecha H, Mason H S, Lane C, et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol, 2003, 77: 8702–8711, 1:CAS:528:DC%2BD3sXmt1Sitrg%3D, 10.1128/JVI.77.16.8702-8711.2003, 12885889
Santi L, Batchelor L, Huang Z, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine, 2008, 26: 1846–1854, 1:CAS:528:DC%2BD1cXjtlWitbc%3D, 10.1016/j.vaccine.2008.01.053, 18325641
Kohl T, Hitzeroth I I, Stewart D, et al. Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: A proof-of-concept study. Clin Vaccine Immunol, 2006, 13: 845–853, 1:CAS:528:DC%2BD28XosFCrsLg%3D, 10.1128/CVI.00072-06, 16893983
Mason H S, Lam D M, Arntzen C J. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA, 1992, 89: 11745–11749, 1:CAS:528:DyaK3sXpsFakug%3D%3D, 10.1073/pnas.89.24.11745, 1465391
Huang Z, Elkin G, Maloney B J, et al. Virus-like particle expression and assembly in plants: Hepatitis B and Norwalk viruses. Vaccine, 2005, 23: 1851–1858, 1:CAS:528:DC%2BD2MXhsleisrc%3D, 10.1016/j.vaccine.2004.11.017, 15734055
Saldana S, Esquivel Guadarrama F, Olivera Flores T de J, et al. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. Viral immunol, 2006, 19: 42–53, 1:CAS:528:DC%2BD28Xis1Grt7w%3D, 10.1089/vim.2006.19.42, 16553549
Greco R, Michel M, Guetard D, et al. Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. Vaccine, 2007, 25: 8228–8240, 1:CAS:528:DC%2BD2sXhtlahurrJ, 10.1016/j.vaccine.2007.09.061, 17976876
Vieira H L, Estevao C, Roldao A, et al. Triple layered rotavirus VLP production: Kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol, 2005, 120: 72–82, 1:CAS:528:DC%2BD2MXhtVyntrzO, 10.1016/j.jbiotec.2005.03.026, 16023241
Roldao A, Vieira H L A, Alves P M, et al. Intracellular dynamics in rotavirus-like particles production: Evaluation of multigene and monocistronic infection strategies. Proc Biochem, 2006, 41: 2188–2199, 1:CAS:528:DC%2BD28Xps1Clt7c%3D, 10.1016/j.procbio.2006.06.019
Petitpas I, Lepault J, Vachette P, et al. Crystallization and preliminary X-ray analysis of rotavirus protein VP6. J Virol, 1998, 72: 7615–7619, 1:CAS:528:DyaK1cXlsVSmtLg%3D, 9696863
Lepault J, Petitpas I, Erk I, et al. Structural polymorphism of the major capsid protein of rotavirus. EMBO J, 2001, 20: 1498–1507, 1:CAS:528:DC%2BD3MXivVCkurY%3D, 10.1093/emboj/20.7.1498, 11285214
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Yang, Y., Li, X., Yang, H. et al. Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants. Sci. China Life Sci. 54, 82–89 (2011). https://doi.org/10.1007/s11427-010-4104-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-010-4104-3